Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for CAL-101 (compound)
Most Correlated Studies
- B cell nascent RNA after treatment with PI3K inhibitors idelalisib or duvelisib
- Diffuse large B-cell lymphoma TMD8 cells resistant to PI3K-delta inhibitor idelalisib
- L1000 CMAP - Motor neuron MNEU.E cells treated with small molecule perturbagens
- L1000 CMAP - Embryonic stem HUES3 cells treated with small molecule perturbagens
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Most Relevant Literature
- CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignan…
- Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strateg…
- PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
- CAL-101,a novel agent of targeted therapy in hematological malignancies].
- Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth…
Most Relevant Clinical Trials
- Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenanc…
- Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an…
- Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
- An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Followin…
- Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-g…
